PMID: 9167457May 24, 1997Paper

Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy

Lancet
A S HallS G Ball

Abstract

In the Acute Infarction Ramipril Efficacy (AIRE) Study, the effect of angiotensin-converting-enzyme (ACE) inhibition on the survival of patients with clinical heart failure after acute myocardial infarction (AMI), was assessed. At an average follow-up time of 15 months after randomisation, all-cause mortality was reduced from 22.6% (placebo group) to 16.9% (ramipril group) representing an absolute mortality reduction of 5.7% and a relative risk reduction of 27% (95% CI 11-40%; p = 0.002). Our aim in this study was to assess the long-term (3 years after the AIRE Study closed) magnitude, duration, and reliability of the survival benefits observed after treatment with ramipril (target dose 5 mg twice a day) when compared with placebo. We investigated the mortality status of all 603 patients recruited from the 30 UK centres involved in the AIRE Study. Through government records we were able to confirm the death or survival of all 603 patients exactly 3 years after the close of the AIRE Study. Follow-up was for a minimum of 42 months and a mean of 59 months. The average duration of treatment with masked trial medication was 13.4 months for placebo and 12.4 months for ramipril. By 0000 h March 1, 1996, death from all causes had occur...Continue Reading

Associated Clinical Trials

References

Oct 8, 1992·The American Journal of Cardiology·UNKNOWN GISSI-3-Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jan 1, 1989·Journal of Cardiovascular Pharmacology·E Ambrosioni, C Borghi
Oct 1, 1995·Journal of Cardiovascular Risk·M TestaT H Lejemtel

❮ Previous
Next ❯

Citations

Mar 24, 2012·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·E BlozikM Scherer
Apr 7, 2006·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Dirk SkowaschGerhard Bauriedel
Mar 17, 2005·Cardiovascular Drugs and Therapy·R M A van de WalD J van Veldhuisen
Jul 28, 2007·Cardiovascular Drugs and Therapy·M L BotsUNKNOWN EUROPA-PERFECT Investigators
Jun 28, 2001·European Journal of Pharmacology·J LevijokiH Haikala
Aug 2, 1997·Lancet·P Dunkley, K Hodgson
Oct 31, 1997·Lancet·M Lye
Jan 26, 2000·International Journal of Cardiology·R Willenheimer
Nov 9, 2000·British Journal of Clinical Pharmacology·S Maxwell, W S Waring
Mar 29, 2008·Metabolic Syndrome and Related Disorders·M A Charles, J L Selam
Sep 18, 1998·BMJ : British Medical Journal·L A Petersen
Nov 25, 2006·BMC Family Practice·Martin SchererMichael M Kochen
Jul 19, 2001·Japanese Journal of Pharmacology·D JinM Miyazaki
May 14, 2009·Vascular Health and Risk Management·David Fitchett
Feb 13, 2001·European Journal of Heart Failure·N GadsbøllP F Høilund-Carlsen
Jun 12, 2009·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Isabella Sudano, Georg Noll
Jul 13, 2007·Kidney International·P A McFarlane
May 31, 2011·The Canadian Journal of Cardiology·Pierre Nantel, Paul René de Cotret
Mar 28, 2007·Heart Failure Clinics·Dhruv Kazi, Anita Deswal
Mar 11, 1998·Lancet·D McNamee
Jan 13, 2006·Preventive Cardiology·Philip R Liebson
Jul 2, 2010·British Journal of Pharmacology·Terry K W MaYat-Yin Lam
Mar 16, 2001·Expert Opinion on Pharmacotherapy·A Prasad, G Reeder
Sep 8, 2005·Expert Opinion on Pharmacotherapy·Michael J Rokoss, Koon K Teo
Jun 13, 2001·Journal of the American College of Cardiology·M E KhalilI A Alhaddad
Mar 25, 2014·Heart Failure Clinics·Anuradha Lala, Akshay S Desai
Nov 9, 2004·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·S D HobbsA W Bradbury
Jul 27, 2006·Progress in Cardiovascular Diseases·Ehud Grossman, Franz H Messerli
Nov 6, 2007·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Ian GrahamUNKNOWN European Atherosclerosis Society (EAS)

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.